© 2024 HSP News Service, L.L.C.
Solid-organ transplant recipients have a higher rate of cancer mortality than what is expected in the general population, according to a Canadian study by Acuna et al published in JAMA Oncology. Cancer mortality among transplant recipients was significantly elevated compared with data for the...
Patients with hepatocellular carcinoma and moderate liver dysfunction can derive benefit from, and be treated safely with, sorafenib (Nexavar), according to the second interim analysis of the GIDEON trial, presented at the 2011 ASCO Annual Meeting by Jorge A. Marrero, MD, of the University of...
Nearly 16,000 people from 16 countries attended this year’s European Multidisciplinary Cancer Congress, held recently in Stockholm. The ASCO Post has featured several key reports from the meeting and will offer further coverage in upcoming issues. Additional noteworthy studies presented at the...
Laparoscopic resection of primary and metastatic liver cancers can be safe and oncologically efficient and reduce postoperative length of stay, a single-center study from the United Kingdom found.1 The investigators cautioned, however, that “adequate patient selection and extensive experience in...
Bone morphogenesis protein 4 (BMP4), which belongs to the transforming growth factor (TGF)-β family, is a multifunctional cytokine that is known to be involved in human carcinogenesis. The cytokine exerts its effects through pathways dependent on and independent of SMAD proteins, which are the...
Designer T cells are modified from normal T cells to express specific immune receptors that allow them, via antibody-directed recognition or other mechanisms, to kill malignant cells bearing particular antigens. The Surgical Immunotherapy Lab at the Roger Williams Medical Center, Providence, Rhode...
From the moment I had a partial hysterectomy in 2010, I started having unexplained bouts of nausea. My surgeon and even my primary care physician chalked it up to everything from the difficult 6-hour surgery I had just had to anxiety over a move I’d recently made from Connecticut to North Carolina. ...
Delcath Systems, Inc, announced that it has submitted a New Drug Application (NDA) to the FDA, seeking approval for its chemosaturation system (CHEMOSAT) for use with melphalan hydrochloride in the treatment of patients with unresectable metastatic melanoma in the liver. The system is designed to...
Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma who received nucleoside analogs after curative liver resection had an associated lower risk of hepatocellular carcinoma in a nationwide cohort study using data from the Taiwan National Health Research Data Base. The study was...
The 10th annual Gastrointestinal Cancers Symposium, held recently in San Francisco, was jointly sponsored by ASCO, the AGA (American Gastroenterological Association), ASTRO (American Society for Radiation Oncology), and the SSO (Society of Surgical Oncology). “We seek to present the newest...
Medical oncologists are apt to underestimate the resectability of liver metastases in patients with colorectal cancer and therefore often fail to refer potential surgical candidates for surgical consultation, according to a study presented at the 18th Annual Conference of the National Comprehensive ...
For the treatment of metastases to the liver and the lung, interventional radiologists reported early success with two novel approaches at the Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, held recently in New Orleans. Cryoablation of Lung Tumors For patients with...
If sorafenib (Nexavar) and local ablation techniques are both effective in the treatment of metastatic hepatocellular carcinoma, could they deliver an even greater punch when combined? The concurrent use of interventional radiology approaches and sorafenib for metastatic hepatocellular carcinoma is ...
In patients with unresectable hepatic metastases from metastatic melanoma and neuroendocrine tumors, radioembolization led to good outcomes in studies from Emory University School of Medicine reported at the 38th Society of Interventional Radiology Annual Scientific Meeting, held recently in New...
This issue of The ASCO Post summarizes the results of an important study recently published in The New England Journal of Medicine by Yong and colleagues. As outlined, investigators from the National University of Singapore Yong Loo Lin School of Medicine have identified re-expression of SALL4 as a ...
Hepatocellular carcinomas with characteristics of embryonic stem cell and progenitor cell gene expression are associated with particularly poor prognosis. SALL4 is an oncofetal protein that is expressed in the human fetal liver and normally silenced in the adult liver, but re-expressed in a...
Hepatocellular carcinoma is a devastating disease worldwide. Although advances in liver transplantation, surgery, and locoregional therapies have made tumor control or even cure possible for a minority of patients, the majority of patients diagnosed with hepatocellular carcinoma will develop...
The investigational drug brivanib is a dual inhibitor of vascular endothelial growth factor and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. The agent was recently evaluated in two phase III trials, one comparing first-line brivanib with sorafenib (Nexavar) in...
Promising efficacy in advanced hepatocellular carcinoma patients was reported for a novel transforming growth factor–beta receptor type 1 (TGF-β1) kinase inhibitor, LY2157299 monohydrate, at the 2014 Gastrointestinal Cancers Symposium in San Francisco.1 In particular, patients with moderate to...
The U.S. Food and Drug Administration has approved ethiodized oil injection (Lipiodol) for selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma. The agent received orphan drug designation for management of patients with known hepatocellular carcinoma ...
CASI Pharmaceuticals, Inc, announced that its investigational agent ENMD-2076 has received orphan drug designation from the U.S. Food & Drug Administration (FDA) for the treatment of hepatocellular carcinoma. ENMD-2076 is an orally active Aurora A/angiogenic kinase inhibitor with a unique...
“Despite the strong scientific rationale and preclinical data, everolimus [Afinitor] plus best supportive care failed to improve survival over placebo plus best supportive care” among patients with advanced hepatocellular cancer that progressed during or after receiving sorafenib (Nexavar), or who...
There is limited evidence of mutation-specific T-cell response to epithelial cancers. In a study reported in Science, Tran and colleagues used whole-exome sequencing to show that tumor-infiltrating lymphocytes included CD4-positive Th1 cells that recognized a mutation in erbb2 interacting protein...
In 1995, I was diagnosed with advanced colorectal cancer and given little chance to live. The dire diagnosis came years after being assured by several physicians that the problem I was having with rectal bleeding and anemia was nothing more than the result of an internal hemorrhoid. Busy raising...
Biliary tract cancers are challenging, but a large genomic profiling study has identified potentially clinically relevant genomic alterations in up to two-thirds of patients.1 “The diverse landscape of clinically relevant genomic alterations in biliary tract cancers can serve as targets for...
“Hepatitis C virus (HCV) infection is a neglected disease in patients with cancer,” Harrys A. Torres, MD, and colleagues from the University of Texas MD Anderson Cancer Center in Houston noted in the Journal of the National Comprehensive Cancer Network. To rectify that situation, the researchers...
A new study presented at The International Liver Congress™ 2015 in Vienna, Austria, showed that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma, it is possible to identify specific molecular profiles. It is hoped that these ...
Nearly 20% of patients with hepatocellular carcinoma “wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth,” Nishant Patel, MD, and colleagues concluded in the Journal of the National Comprehensive Cancer Network. They based their conclusions on a...
Nearly 20% of patients with hepatocellular carcinoma “wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth,” Nishant Patel, MD, and colleagues concluded in the Journal of the National Comprehensive Cancer Network. They based their conclusions on a...
Two “firsts” in studies of colorectal liver metastases were highlighted at the 2015 ASCO Annual Meeting: the first prospective randomized trial to evaluate radiofrequency ablation plus chemotherapy1 and the first large randomized phase III trial to study liver-directed selective internal radiation...
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Wahl et al found that stereotactic body radiotherapy may provide better freedom from local tumor progression vs radiofrequency ablation in patients with inoperable nonmetastatic larger hepatocellular...
In the phase III STORM trial reported in The Lancet Oncology, Bruix et al found no benefit with adjuvant sorafenib (Nexavar) treatment in patients who had undergone resection or ablation for hepatocellular carcinoma. Study Details In this double-blind trial, 1,114 patients from 202 sites in 28...
More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus. Researchers at Inserm, the Paris Public Hospitals (AP-HP), Paris...
In a UK randomized phase II trial (ABC-03) reported in The Lancet Oncology, Valle et al found that adding the VEGF inhibitor cediranib to first-line cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer. Study Details In the double-blind...
Delcath Systems, Inc, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug designation to melphalan for the treatment of cholangiocarcinoma. Cholangiocarcinoma is recognized by the FDA as an orphan disease,...
In a study reported in The Lancet Oncology, Lin et al developed a serum microRNA classifier that was more accurate than alpha-fetoprotein in detecting preclinical hepatocellular carcinoma. Study Details The study involved healthy controls, inactive hepatitis B surface antigen carriers,...
In the phase III REACH trial reported in The Lancet Oncology, Zhu et al found that the anti-VEGFR2 monoclonal antibody ramucirumab (Cyramza) did not significantly improve overall survival vs placebo in patients with advanced hepatocellular carcinoma who had received first-line treatment with the...
New research published by Søgaard et al in Blood found that blood clots in the abdominal veins might be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. Clotting and Cancer Risk Compared to...
In the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have similar beneficial outcomes whether using organs donated by patients after cardiac death or brain death. The study was recently published by Croome et al in the American...
Significant clinical variations exist among patients with the most common type of liver cancer, hepatocellular carcinoma, depending on the viral cause of the disease—hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when...
A phase I/II study testing the safety and antitumor activity of nivolumab (Opdivo) in advanced hepatocellular carcinoma has revealed one of the first signs that immunotherapy with immune checkpoint inhibitors will have a role in the treatment of liver cancer. The results and potential implications...
Nearly 20% of patients with hepatocellular carcinoma “wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth,” Patel et al concluded in the Journal of the National Comprehensive Cancer Network. They based their conclusions on a review of...
In a study reported in JAMA Surgery, Spolverato et al derived 3-year conditional survival estimates for patients in a multi-institutional database who underwent liver resection for intrahepatic cholangiocarcinoma. Among all patients, actuarial overall survival was 16% at 8 years, whereas 3-year...
A new study presented at The International Liver Congress 2015 in Vienna showed that using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma may make it possible to identify specific molecular profiles linked to tumor aggressiveness...
Results presented on April 24 at The International Liver Congress 2015 (Abstract O058) in Vienna, Austria, show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV...
In a study reported in the Journal of the National Cancer Institute, McGlynn et al found that statin use was associated with a reduced risk of primary liver cancer in a setting of low liver cancer prevalence. Other studies have shown a preventive benefit of statin therapy in regions of the world...
In a study reported in the Journal of Clinical Oncology, Ostronoff et al found that the presence of the NPM1-positive/FLT3-internal tandem duplication (ITD)–negative genotype—which is recognized as a marker of better prognosis in younger patients with acute myeloid leukemia—was...
According to researchers at Memorial Sloan Kettering Cancer Center (MSKCC), hepatic parenchymal preservation, in which a surgeon removes less than a lobe of the liver in a patient undergoing an operation for liver cancer, is associated with lower mortality and complication rates. Their study...
In a Chinese study reported in the Journal of Clinical Oncology, Ren et al found that prophylactic use of urea-based cream reduced the incidence of sorafenib (Nexavar)–associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. Urea-based creams are used to treat...
In the phase III SEARCH trial reported in the Journal of Clinical Oncology, Zhu et al found no overall survival benefit of adding erlotinib (Tarceva) to sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. Study Details In this double-blind trial conducted in 26 countries in...